We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novelion Therapeutics Inc | NASDAQ:NVLN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.68 | 0.63 | 0.6677 | 0 | 01:00:00 |
CUSIP No. 67001K202
|
Page 1 of 7 Pages
|
Novelion Therapeutics Inc.
|
(Name of Issuer)
|
Common Stock, without par value
|
(Title of Class of Securities)
|
|
67001K202
|
(CUSIP Number)
|
Mark DiPaolo
General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
203-302-2330
With a copy to:
Russell Leaf
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
212-728-8000
|
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications) |
June 29, 2017
|
(Date of Event which Requires Filing of this Statement)
|
CUSIP No. 67001K202
|
Page 2 of 7 Pages
|
1
|
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sarissa Capital Management LP |
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐
(b)
☐
|
|||
3
|
SEC USE ONLY
|
||||
4
|
SOURCE OF FUNDS
WC |
||||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
|
☐
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
||||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
|
|||
8
|
SHARED VOTING POWER
1,025,000 |
||||
9
|
SOLE DISPOSITIVE POWER
|
||||
10
|
SHARED DISPOSITIVE POWER
1,025,000 |
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,025,000 |
||||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
|
☐
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.5% |
||||
14
|
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 67001K202
|
Page 3 of 7 Pages
|
1
|
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Alexander J. Denner, Ph.D. |
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐
(b)
☐
|
|||
3
|
SEC USE ONLY
|
||||
4
|
SOURCE OF FUNDS
WC |
||||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
|
☐
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
||||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
|
|||
8
|
SHARED VOTING POWER
1,025,000 |
||||
9
|
SOLE DISPOSITIVE POWER
|
||||
10
|
SHARED DISPOSITIVE POWER
1,025,000 |
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,025,000 |
||||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
|
☐
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.5% |
||||
14
|
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 67001K202
|
Page 4 of 7 Pages
|
1
|
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sarissa Capital Offshore Master Fund LP |
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐
(b)
☐
|
|||
3
|
SEC USE ONLY
|
||||
4
|
SOURCE OF FUNDS
WC |
||||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
|
☐
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands |
||||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
458,766 |
|||
8
|
SHARED VOTING POWER
|
||||
9
|
SOLE DISPOSITIVE POWER
458,766 |
||||
10
|
SHARED DISPOSITIVE POWER
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
458,766 |
||||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
|
☐
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.5% |
||||
14
|
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 67001K202
|
Page 5 of 7 Pages
|
1
|
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sarissa Capital Domestic Fund LP |
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐
(b)
☐
|
|||
3
|
SEC USE ONLY
|
||||
4
|
SOURCE OF FUNDS
WC |
||||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
|
☐
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
||||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
566,234 |
|||
8
|
SHARED VOTING POWER
|
||||
9
|
SOLE DISPOSITIVE POWER
566,234 |
||||
10
|
SHARED DISPOSITIVE POWER
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
566,234 |
||||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
|
☐
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.0% |
||||
14
|
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 67001K202
|
Page 6 of 7 Pages
|
CUSIP No. 67001K202
|
Page 7 of 7 Pages
|
By:
|
/s/ Mark DiPaolo
|
Name: Mark DiPaolo
|
|
Title: General Counsel
|
By:
|
/s/ Mark DiPaolo
|
Name: Mark DiPaolo
|
|
Title: Authorized Person
|
By:
|
/s/ Mark DiPaolo
|
Name: Mark DiPaolo
|
|
Title: Authorized Person
|
1 Year Novelion Therapeutics Chart |
1 Month Novelion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions